Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XLF055 plus metronidazole to prevent recurrence of bacterial vaginosis
ChiCTR2500109411Phase 3Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Sep 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Bi-Live in bacterial vaginosis (BV) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Recurrence rate of bacterial vaginosis within 90 days after treatment. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
Bi-Live
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on ChiCTR2500109411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109411.